Savara Aktie [WKN DE: A2DQ2B / ISIN: US8051111016]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Savara Inc Registered Shs

22.11.22		Savara Announces New Employment Inducement Grant (Businesswire)
10.11.22		Savara Reports Third Quarter 2022 Financial Results and Provides Business Update (Businesswire)
09.11.22		Savara to Participate in Three Upcoming Investor Conferences (Businesswire)
14.09.22		Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
06.09.22		Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022 (Businesswire)
01.09.22		Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference (Businesswire)
26.08.22		Savara Announces Resignation of Chief Medical Officer (Businesswire)
25.08.22		Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Businesswire)
11.08.22		Savara Reports Second Quarter 2022 Financial Results and Provides Business Update (Businesswire)
11.07.22		Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022 (Businesswire)
16.06.22		Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic (Businesswire)
01.06.22		Savara to Present at Jefferies Healthcare Conference (Businesswire)
17.05.22		Savara to Present at H.C. Wainwright Global Investment Conference (Businesswire)
11.05.22		Savara Reports First Quarter 2022 Financial Results and Provides Business Update (Businesswire)
26.04.22		Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
22.04.22		Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank (Businesswire)
30.03.22		Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update (Businesswire)
16.03.22		Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
09.03.22		Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference (Businesswire)
04.01.22		Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (Businesswire)
02.12.21		Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
30.06.21		Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial (Businesswire)
26.05.21		Savara to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
17.05.21		Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit (Businesswire)
14.05.21		Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
13.05.21		Savara Reports First Quarter 2021 Financial Results and Provides Business Update (Businesswire)
15.03.21		Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters’ Option (Businesswire)
11.03.21		Savara Announces Pricing of Public Offering of Common Stock (Businesswire)
10.03.21		Savara Announces Proposed Public Offering of Common Stock (Businesswire)
24.02.21		BLUE To Face FDA Next Month, SNSS Catches Eyes, ADVM On Watch (RTTNews)
10.12.20		Savara Provides Pipeline and Business Update (Businesswire)
24.11.20		Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences (Businesswire)
11.11.20		Savara to Present at the Jefferies Virtual London Healthcare Conference (Businesswire)
05.11.20		Savara Reports Third Quarter 2020 Financial Results and Provides Business Update (Businesswire)
11.09.20		Savara Announces Senior Management Changes (Businesswire)
09.09.20		Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually (Businesswire)
08.09.20		Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results (Businesswire)
03.09.20		Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF) (Businesswire)
06.08.20		Savara Reports Second Quarter 2020 Financial Results and Provides Business Update (Businesswire)
05.08.20		Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually (Businesswire)
30.07.20		Savara to Report Second Quarter 2020 Financial Results and Provide Business Update (Businesswire)
27.05.20		Savara to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
08.05.20		Savara Announces Change of Date for 2020 Annual Meeting of Stockholders (Businesswire)
07.05.20		Savara Reports First Quarter 2020 Financial Results and Provides Business Update (Businesswire)
30.04.20		Savara to Report First Quarter 2020 Financial Results and Provide Business Update (Businesswire)
02.04.20		Savara Obtains Global Rights to Develop and Commercialize Apulmiq (Businesswire)
31.03.20		AMRN Loses Legal Fight, AKRO Awaits Big Day, JNJ's Covid-19 Vaccine Study In Sep (RTTNews)
30.03.20		Savara Provides Business Update in Response to COVID-19 Pandemic (Businesswire)
12.03.20		Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update (Businesswire)
05.03.20		Savara to Report Fourth Quarter/Year-End 2019 Financial Results and Provide Business Update (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

Ripple steigt deutlich: Neues ATH noch in 2024?

voestalpine-Aktie zieht an: Erste Group stuft Aktie von "Accumulate" auf "Buy" hoch

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Diese Aktien empfehlen Experten zu kaufen

Pierer Mobility-Aktie unter Druck: KTM-Pleite - Schockstarre in der Region und bei den Zulieferern - Land OÖ signalisiert Bereitschaft Beschäftigten zu helfen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	02.12.2024 13:35
Kaufwert:	EUR
	Hinzufügen Speichern